Literature DB >> 3035002

Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

G Plewe, U Schneider, U Krause, J Beyer.   

Abstract

Opiates stimulate the growth hormone and prolactin responses to stimuli in non-obese humans. Obese patients, however, show lowered growth hormone and prolactin responses and raised beta-endorphin levels. We therefore investigated the effect of the opiate antagonist naloxone on the stimulated growth hormone and prolactin secretions in a controlled double-blind study in obese patients. All patients received 200 micrograms TRH and 0.5 g/kg b.w. arginine together with 2 mg of naloxone or placebo i.v. in a randomized sequence. The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Naloxone also produced a significant increase in ACTH, cortisol and beta-endorphin when compared with placebo. TSH, triiodothyronine, thyroxine, insulin, glucagon and blood glucose showed no significant differences between both days of the trial. The effect of naloxone on growth hormone and prolactin secretions in obese humans can thus be regarded as a partial normalization. We therefore conclude that the hypothalamic regulatory disturbance of growth hormone and prolactin secretions in the obese could be caused by raised opiate levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035002     DOI: 10.1007/BF03347177

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Failure of naloxone to influence physiological growth hormone and prolactin secretion.

Authors:  J B Martin; G Tolis; I Woods; H Guyda
Journal:  Brain Res       Date:  1979-05-18       Impact factor: 3.252

2.  Lack of modulation of pituitary hormone stress response by neural pathways involving opiate receptors.

Authors:  I J Spiler; M E Molitch
Journal:  J Clin Endocrinol Metab       Date:  1980-03       Impact factor: 5.958

3.  Endocrine effects of naloxone-induced opiate receptor blockade.

Authors:  J E Morley; N G Baranetsky; T D Wingert; H E Carlson; J M Hershman; S Melmed; S R Levin; K R Jamison; R Weitzman; R J Chang; A A Varner
Journal:  J Clin Endocrinol Metab       Date:  1980-02       Impact factor: 5.958

4.  The role of opioid peptides in the hormonal responses to acute exercise in man.

Authors:  A Grossman; P Bouloux; P Price; P L Drury; K S Lam; T Turner; J Thomas; G M Besser; J Sutton
Journal:  Clin Sci (Lond)       Date:  1984-11       Impact factor: 6.124

5.  Altered hypothalamic and sympathetic responses to hypoglycaemia in familial obesity.

Authors:  R T Jung; R G Campbell; W P James; B A Callingham
Journal:  Lancet       Date:  1982-05-08       Impact factor: 79.321

6.  Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction.

Authors:  T Williams; M Berelowitz; S N Joffe; M O Thorner; J Rivier; W Vale; L A Frohman
Journal:  N Engl J Med       Date:  1984-11-29       Impact factor: 91.245

7.  beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland.

Authors:  R Guillemin; T Vargo; J Rossier; S Minick; N Ling; C Rivier; W Vale; F Bloom
Journal:  Science       Date:  1977-09-30       Impact factor: 47.728

8.  Failure of naloxone to influence plasma growth hormone, prolactin, and cortisol secretions induced by insulin hypoglycemia.

Authors:  I Wakabayashi; R Demura; N Miki; E Ohmura; H Miyoshi; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1980-03       Impact factor: 5.958

9.  Impaired hypothalamic control of prolactin secretion in massive obesity.

Authors:  P G Kopelman; N White; T R Pilkington; S L Jeffcoate
Journal:  Lancet       Date:  1979-04-07       Impact factor: 79.321

10.  Naloxone-induced prolactin secretion in women: evidence against a direct prolactin stimulatory effect of endogenous opioids.

Authors:  N S Cetel; M E Quigley; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1985-01       Impact factor: 5.958

View more
  4 in total

Review 1.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

2.  Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men.

Authors:  V Coiro; L Capretti; G Speroni; A Castelli; L Bianconi; U Cavazzini; A Marcato; R Volpi; P Chiodera
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

3.  Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects.

Authors:  D Papalia; M Lunetta; M Di Mauro
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

Review 4.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.